Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib plus oral vinorelbine in first-line treatment for EGFR-mutant advanced NSCLC with ECOG 2–4
ChiCTR2600121540Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib and vinorelbine in non-small cell lung cancer (NSCLC) and bronchial carcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoint: progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
almonertinibvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2600121540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121540.